By Prime Law Hub 
The Zealthy Lawsuit refers to an ongoing federal civil enforcement action brought by the United States against telehealth company Zealthy Inc. (also known as Gronk Inc.), its affiliated medical entity Bruno Health P.A., founder and CEO Kyle Robertson, and medical director German Echeverry. Filed in the U.S. District Court for the Southern District of Florida, the case centers on allegations of unfair and deceptive business practices, violations of federal consumer protection laws governing online subscriptions, and more recent claims of improper prescribing practices that the government says endangered patients.
This article provides a clear, factual breakdown of the Zealthy Lawsuit based on court filings and public statements from the Department of Justice (DOJ) and Federal Trade Commission (FTC). It explains the legal framework, key allegations, procedural developments, and potential outcomes while distinguishing between proven facts and government allegations. Readers should note that allegations in a complaint do not constitute findings of liability. Defendants have the opportunity to contest all claims, and the case remains ongoing as of May 2026.
Background on Zealthy and Its Connection to Prior Telehealth Enforcement
Zealthy launched as a telehealth platform offering services in areas such as weight management (including compounded GLP-1 medications), mental health support, erectile dysfunction, skincare, and hormone-related care. Kyle Robertson, who previously co-founded and led Cerebral Inc., established Zealthy after departing Cerebral in 2022. German Echeverry served as the medical director for the affiliated professional association, Bruno Health P.A.
The Zealthy Lawsuit builds directly on enforcement actions against Cerebral. In June 2024, the DOJ and FTC filed an amended complaint that included both Cerebral and Zealthy. Cerebral reached a settlement with the government that included consumer redress payments and suspended civil penalties. The claims against Zealthy, Robertson, Echeverry, and Bruno Health continued and later expanded.
Zealthy operated a subscription-based model typical of direct-to-consumer telehealth platforms. Consumers enrolled online, provided payment information, and received ongoing access to consultations and medications. The government alleges that core aspects of this model violated federal rules designed to protect consumers from unexpected recurring charges and opaque practices.
Core Allegations from the 2024 Complaint: ROSCA and Deceptive Practices
The primary claims in the initial and first amended complaints focus on two federal statutes: the Restore Online Shoppers’ Confidence Act (ROSCA) and Section 5 of the Federal Trade Commission Act.
ROSCA, enacted by Congress, addresses “negative option” marketing common in online subscriptions. It requires sellers to:
- Clearly and conspicuously disclose all material terms before obtaining a consumer’s billing information.
- Obtain the consumer’s express informed consent to those terms before charging.
- Provide a simple mechanism for consumers to stop recurring charges.
According to the complaint, Zealthy and Bruno Health allegedly failed on all three fronts. Enrollment flows reportedly presented low or promotional pricing (such as “$0 today” or low first-month fees) while material terms about total costs, automatic renewal, cancellation restrictions, and data practices appeared only in fine print or separate pages not presented during signup. Consumers allegedly faced charges significantly higher than expected, sometimes exceeding $1,000 in early periods.
Cancellation presented another alleged barrier. Despite marketing language suggesting easy cancellation, the government claims consumers encountered complicated processes involving repeated emails or calls rather than a straightforward online option. The complaint states that charges continued even after cancellation attempts.
On the privacy side, the complaint alleges that Zealthy and Bruno Health collected sensitive health information and used or disclosed it in ways not clearly disclosed during enrollment. Marketing allegedly relied on targeted advertising derived from user data without adequate consent. These practices, if proven, would violate both ROSCA disclosure requirements and the FTC Act’s prohibition on unfair or deceptive acts or practices.
The complaint emphasizes that Robertson brought knowledge of these legal requirements from his time at Cerebral, where similar issues had surfaced. This knowledge is imputed to the new entities under his direction.
2026 Developments: Expanded Allegations on Prescribing Practices and Asset Preservation
In April 2026, the government filed further amendments and a motion seeking an immediate asset freeze and the appointment of a receiver over Zealthy and Robertson. These filings introduced significantly more serious allegations drawn from discovery in the ongoing case.
The DOJ described Zealthy’s operations as involving a “runaway campaign of lawbreaking.” New claims include:
- Routine ordering of prescriptions by non-clinicians, including foreign call-center contractors lacking medical licenses.
- Systematic misuse of physicians’ names and National Provider Identifier (NPI) numbers to generate thousands of prescriptions for patients the named doctors had not treated or even seen, and without the doctors’ knowledge or clinical supervision. One cited example involved more than 8,000 prescriptions attributed to a single doctor after that physician had left the organization.
- Continued deceptive billing and subscription practices similar to those alleged earlier, including misleading pricing claims and obstacles to cancellation.
The government argues these practices not only deceived consumers but also posed direct risks to patient safety by bypassing proper medical oversight.
Additionally, the filings note that Zealthy lost its LegitScript medical merchant certification in January 2025 after failing to disclose the existence of the federal lawsuit. The government alleges that the company subsequently used shell companies to process payments and maintain operations.
Why the Government Seeks Asset Freeze and Receivership
In support of its April 2026 motion, the DOJ argued that an asset freeze and receivership are necessary to prevent dissipation of assets, protect consumers, and preserve the possibility of meaningful redress. Receivership involves a court-appointed neutral party taking control of a company’s operations and assets to manage them during litigation, often used in cases involving alleged fraud or ongoing harm.
The government stated that consumer redress and potential civil penalties could be substantial enough to affect Zealthy’s viability, making preservation of assets essential. It further contended that Robertson and the company have both the incentive and means to continue challenged practices absent court intervention.
As of mid-May 2026, the motion for asset freeze and receivership remains a pending development in the case. No final ruling on that specific request has been widely reported.
Legal Framework and Standards Applied
The Zealthy Lawsuit illustrates how federal consumer protection and telehealth oversight intersect. ROSCA provides specific, enforceable requirements for any seller using negative-option features online. The FTC Act gives the Commission (and the DOJ in certain referrals) broad authority to address deceptive or unfair practices affecting commerce.
Courts evaluate these claims under established standards. For deception, the analysis typically considers whether a representation or omission is likely to mislead a reasonable consumer acting under the circumstances. For unfairness, the focus is on substantial injury that consumers cannot reasonably avoid and that is not outweighed by countervailing benefits.
Individual liability for corporate officers such as Robertson and Echeverry requires showing that the individual participated directly in the violations or had authority to control the practices and knew or should have known about them. The complaint alleges both participation and control.
These standards derive from decades of FTC enforcement and judicial precedent in subscription, telemarketing, and healthcare marketing cases. Telehealth companies, like any online seller of recurring services, must maintain robust compliance programs covering disclosure, consent, cancellation, data handling, and clinical oversight.
Impact on Consumers
Tens of thousands of individuals may have interacted with Zealthy’s platform. Alleged harms include unexpected recurring charges, difficulty exiting subscriptions, potential exposure to prescriptions issued without proper physician involvement, and use of personal health information in ways consumers did not anticipate.
Consumers who believe they were affected may have options such as disputing charges with their card issuer under the Fair Credit Billing Act (for certain billing errors), filing complaints with the FTC or state attorneys general, or seeking private counsel to evaluate individual claims. Widespread issues sometimes lead to separate class-action litigation, although the primary action discussed here is the government enforcement proceeding.
Patient safety concerns arising from the prescribing allegations, if substantiated, represent a distinct category of potential harm beyond financial injury.
Possible Outcomes and Procedural Path Forward
Because the Zealthy Lawsuit is civil rather than criminal, outcomes typically involve injunctive relief, monetary payments for consumer redress, and civil penalties rather than incarceration. Several paths remain possible:
- Resolution of the asset freeze motion: The court could grant, deny, or modify the request for a freeze and receiver. A granted motion would place operations under external control and restrict asset movement pending further proceedings.
- Settlement: Many FTC and DOJ consumer protection cases resolve through negotiated orders. Cerebral’s earlier resolution included redress payments and suspended penalties tied to ability to pay, plus compliance obligations. A similar structure for Zealthy could include monetary relief for affected consumers, bans on certain practices, and ongoing monitoring.
- Litigation through trial: If no settlement occurs, the case could proceed to summary judgment motions and, if necessary, trial on the merits. Defendants would present defenses, including challenges to the scope of disclosures, evidence of consent, or the characterization of clinical practices.
- Individual versus corporate liability: Even if corporate entities face significant exposure, personal liability for executives depends on specific evidence of their involvement and knowledge.
- Appeals: Any final judgment or significant interim ruling could be appealed to the U.S. Court of Appeals for the Eleventh Circuit.
The government has indicated that the scale of potential liability could strain Zealthy’s resources, which is one reason it seeks asset preservation now. Defendants may argue that the practices complied with applicable standards or that any issues were isolated rather than systemic.
Broader Context for Telehealth Compliance
The Zealthy Lawsuit forms part of sustained federal attention to telehealth business practices following the rapid expansion during and after the COVID-19 public health emergency. Regulators have focused on billing transparency, data privacy under laws such as HIPAA where applicable, clinical appropriateness of prescribing, and marketing claims.
Companies operating in this space face expectations around clear subscription terms, verifiable clinical workflows with licensed professionals exercising independent judgment, and honest representations about costs and cancellation. Loss of credentialing (such as LegitScript) can further complicate payment processing and operations, as seen in the filings.
Important Disclaimers and Practical Notes
This article is for informational purposes only and does not constitute legal advice. It summarizes publicly available information from court filings and government statements regarding the Zealthy Lawsuit. Court documents contain allegations that have not been proven in court. Defendants are presumed innocent until proven otherwise or until they admit wrongdoing through settlement.
Individuals who used Zealthy services and have concerns about billing, cancellation, or medical care should:
- Review their account statements and transaction history.
- Contact their financial institution promptly regarding disputed charges.
- File complaints with the FTC at ReportFraud.ftc.gov or their state attorney general’s consumer protection division.
- Consult a qualified attorney licensed in their jurisdiction for personalized guidance.
Regulatory developments can move quickly. Interested parties should monitor the docket in the Southern District of Florida case for official updates.
Conclusion
The Zealthy Lawsuit highlights critical compliance obligations for telehealth providers in subscription billing, clinical oversight, and consumer disclosures. The government’s allegations span traditional consumer protection concerns under ROSCA and the FTC Act as well as newer claims involving the integrity of the prescribing process itself. With a motion for asset freeze and receivership pending and the case actively litigated, the coming months will likely bring further clarity on both procedural preservation measures and the ultimate resolution path.
For consumers, professionals, and industry participants, the proceedings underscore the importance of transparent practices and robust clinical governance. As enforcement continues in the telehealth sector, companies that prioritize clear consumer communications and proper medical protocols position themselves to avoid similar scrutiny. The Zealthy Lawsuit will likely serve as a reference point for how regulators and courts apply established legal standards to evolving digital health business models.
You May Also Like: Edward Jones Kingsview Advisors Lawsuit: A Complete Overview